Audenz (influenza A (H5N1) monovalent vaccine adjuvanted) / CSL Behring - LARVOL DELTA

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions. (PubMed, Vaccines (Basel)) - " The aH5N1 vaccine had a clinically acceptable safety and tolerability profile with an AE profile comparable to that observed in previous aH5N1 studies. These findings support the viability of aH5N1 as a pre-pandemic influenza vaccine for the immunization of at-risk individuals when an antigenically matched pandemic influenza vaccine is not yet available."

Journal • Geriatric Disorders • Hematological Disorders • Infectious Disease • Influenza • Respiratory Diseases

A Randomized Study to Evaluate the Efficacy of a Cell-Based Quadrivalent Influenza Vaccine Compared to a Non-Influenza Vaccine in Children 6 Months to 47 Months of Age (PAS 2025) - No abstract available

Clinical • Infectious Disease • Influenza • Respiratory Diseases

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study (ASH 2024) - "This study also emphasizes the clinical impact of BKVD, demonstrating a significant association with increased risk of NRM after allo-HCT. These findings highlight the need to develop anti-BK virus therapeutics, including cellular therapies, to improve patient outcomes."

Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Pain • Transplantation

Burden of Severe ANCA Associated Vasculitis in Australia via Real-World Usage of Rituximab (ISPOR-EU 2024) - " Patients diagnosed with severe AAV in Australia are initially treated with one of two treatments as induction therapy, rituximab (RTX) or cyclophosphamide (CYC)... The incidence of patients with severe AAV treated in Australia is likely to be higher than previous studies have shown."

Clinical • Real-world • Real-world evidence • ANCA Vasculitis • Rare Diseases • Vasculitis

Update and narrative review of avian influenza (H5N1) infection in adult patients. (PubMed, Pharmacotherapy) - "This includes a cell-based vaccine approved by the FDA for people aged 6 months and older who are at higher risk of exposure to the H5N1 virus called Audenz...Neuraminidase inhibitors are the mainstay of the avian influenza treatment and includes oseltamivir, peramivir, and zanamivir. Baloxavir marboxil is a cap-dependent endonuclease inhibitor. This clinical review aims to highlight the background, epidemiology, clinical presentation, complications and current treatment and prevention strategies for avian influenza H5N1."

Journal • Review • Infectious Disease • Influenza • Respiratory Diseases

Cost-Effectiveness of Difelikefalin Compared to Best Supportive Care for Treatment of Chronic Kidney Disease-Associated Pruritus in Australia (ISPOR-EU 2024) - "Difelikefalin for treatment of CKD-aP in haemodialysis patients is an effective and cost-effective intervention relative to current practice in Australia. Conflict of interest: Study sponsored by CSL Seqirus Australia."

Cost effectiveness • HEOR • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease

Title TBC (WVCE 2024) - No abstract available

From policy to practice: navigating the COVID-19 vaccination landscape in Europe (WVCE 2024) - No abstract available

Infectious Disease • Novel Coronavirus Disease

Avian influenza: A case study for vaccinating livestock (WVCE 2024) - "- The impact of vaccination on managing disease outbreaks - what have we learnt from French programs?- The economic impact of vaccination on trade- Matching our vaccines to the circulating strains- Monitoring disease epidemiology and spill over to mammals, will this be the next human pandemic?- Does livestock vaccination protect human health?"

Case study • Clinical • Infectious Disease • Influenza • Respiratory Diseases

Biothreats & Disease X Workshop [AM2] (WVCE 2024) - "Sponsored by: Pfizer"

Industry Symposium: CSL Seqirus Strengthening Influenza Protection: A symposium on paediatric, pandemic and pioneering solutions (ISIRV-OPTIONS XII 2024) - "Sponsored by CSL Seqirus"

Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Estimated Additional Burden Averted for the 2022-2023 influenza season from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States (IDWeek 2024) - No abstract available

Infectious Disease • Influenza

Relative Effectiveness of Cell-Based Influenza Vaccines versus Egg-Based Influenza Vaccines: A Review of Test-Confirmed and Clinical Diagnosis-Based Outcomes (IDWeek 2024) - No abstract available

Clinical • Review • Infectious Disease • Influenza

The Impact of Low Influenza Immunization rates on U.S. Hospital System Resources. A Dynamic Model estimation. (IDWeek 2024) - No abstract available

Clinical • Infectious Disease • Influenza

Relative Vaccine Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines Against Test-Confirmed Influenza in the United States 2022-23 Influenza Season (IDWeek 2024) - No abstract available

Infectious Disease • Influenza

Modelling the Relative Vaccine Effectiveness of ARCT-154 versus BNT162b2 in Younger and Older Adults (IDWeek 2024) - No abstract available

Clinical • Infectious Disease • Novel Coronavirus Disease

Modelling the Relative Vaccine Effectiveness of ARCT-154 versus BNT162b2 using Immunogenicity Data (IDWeek 2024) - No abstract available

Infectious Disease • Novel Coronavirus Disease

A Clinical and Economic Comparison of Non-Egg Influenza Vaccines in Adults 18-64 Years in the U.S. (IDWeek 2024) - No abstract available

Clinical • Infectious Disease • Influenza

Conservation of major antigenic sites within each antigenic lineage underpins immunological imprinting to the influenza B virus haemagglutinin (V-Congress 2024) - No abstract available

Infectious Disease • Influenza • Respiratory Diseases

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions. (PubMed, Vaccines (Basel)) - "No serious adverse events or deaths were considered related to the study vaccine. In conclusion, aH5N1 increased antibody responses regardless of age or health status and demonstrated a clinically acceptable safety and tolerability profile."

Clinical • Journal • Fatigue • Geriatric Disorders • Infectious Disease • Influenza • Musculoskeletal Pain • Pain • Respiratory Diseases

The Cost-Effectiveness of the Influenza Cell-Based Vaccine in the U.S. Pediatric Population. A Dynamic Transmission Modelling Approach (PAS 2024) - "Within a low incidence season (LIS), switching from QIVe to QIVc in 6 months- to 17-year-olds may prevent 2.9 million symptomatic cases, 1.1 million outpatient visits, 31,667 hospitalizations, and 4,163 deaths annually. As an opposite, within a high incidence season (HIS), switching from QIVe to QIVc may prevent 1.7 million symptomatic cases, 648,263 outpatient visits, 16,688 hospitalizations, and 2,126 deaths. In both scenarios, LIS and HIS, QIVc would be a cost-saving strategy with US$1.4B and US$468.7M savings from a societal perspective and US$989.8M and US$252.8M savings from a payer perspective, respectively."

Clinical • Cost effectiveness • HEOR • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Estimated Additional Burden Averted from Use of Cell-Based Influenza Vaccines Compared to Egg-Based Influenza Vaccines Among People 0-64 Years of Age in the United States: 2017-2020 Seasons (PAS 2024) - "Figure 1 shows the anticipated number influenza-related cases and complications that would be averted if all vaccinated people 0-64 years of age received IIV4c or IIV4. Across the 3 influenza seasons, use of IIV4c would result in prevention of an additional 12,706,837 symptomatic illnesses, 6,222,820 outpatient visits, 80,390 hospitalizations, and 2,765 deaths. DSA results showed that the rVE estimate was associated with the most variability while the burden estimates were most influential in the other two seasons."

Infectious Disease • Influenza • Respiratory Diseases

Env-Y, a Novel Recombinant Protein to Improve Lentiviral Yield and Quality in Production and Purification (ASGCT 2024) - "Importantly, subsequent re-exposure of these cells to Env-Y at pH 7.4 showed binding at >95% of the level observed prior to dissociation, demonstrating that the VSV-G returned to pre-fusion conformation.Env-Y was able to neutralize LVV in an infectivity assay, reducing transduction of HEK293T cells in a concentration-dependent manner up to 85%. Lentiviral purification of Env-Y-bound LVV using protein A capture and mildly acidic elution condition (pH6) and EDTA was shown in principle and requires further optimization.These data show promise for the concept of the application of Env-Y in in upstream and downstream LVV production process, to increase yield and quality of LVV and reducing cost of LVV manufacturing."

Dyslipidemia • Gene Therapies • Infectious Disease • LDLR

Clinical and Economic Benefits of Adjuvanted and High-Dose Influenza Vaccines in the Elderly in Argentina (ISPOR 2024) - "In Argentina, the use of enhanced influenza vaccines in the elderly can increase vaccine effectiveness, reduce mortality and disease-related costs. Based on comparable vaccine effectiveness, significant economic advantages favor the MF59-adjuvanted inactivated influenza vaccine strategy due its expected lower acquisition costs."

Clinical • HEOR • Infectious Disease • Influenza • Respiratory Diseases

The impact of influenza vaccines on hospitalization costs for older adults in the United States: A real-world economic assessment of adjuvanted trivalent influenza vaccine compared with quadrivalent standard influenza vaccine for the 2018-19 and 2019-20 influenza seasons (AMCP 2024) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Influenza • Respiratory Diseases